By Prakhar Srivastava (Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 ...

now popular weight loss medications, on adverse mental health outcomes." Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs.

If any more evidence were needed of a bounceback in venture financing for biotechs after a dip in 2023, the $400 million first round just announced by Mirador Therapeutics should suffice.